Peter David Suzdak
Direttore/Membro del Consiglio presso Acidophil LLC
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| John McManus | M | 60 | 19 anni | |
| Philip Goelet | M | - |
Acidophil LLC
 Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | 18 anni |
| Lars Fruergaard Jorgensen | M | 58 | 33 anni | |
| Sydney Brenner | M | - |
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | 18 anni |
| Jeffrey Scott | M | 67 | 11 anni | |
| John Clerici | M | 54 | 11 anni | |
| Amit Kumar | M | 59 | 20 anni | |
| Chris Rallis | M | 70 | 20 anni | |
| John Farah | M | 72 | 19 anni | |
| Mitchell Kaye | M | 56 | 11 anni | |
| Martin A. Mullins | M | - |
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | - |
| Simon Aspland | M | - |
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | 22 anni |
| Kathy Miller | F | - |
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | - |
| Maziar Mike Doustdar | M | 54 | 32 anni | |
| John Halberstadt | M | - |
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Douglas Swirsky | M | 54 | 2 anni | |
| Russell Skibsted | M | 65 | 3 anni | |
| Chang Ho Ahn | M | 72 | 16 anni | |
| Michael P. McManus | M | 54 | 5 anni | |
| Tae Heum Jeong | M | 53 | 15 anni | |
| David H. Bergstrom | M | 70 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 1 anni |
| Kåre Schultz | M | 62 | 26 anni | |
| Lise Kingo | F | 62 | 26 anni | |
| Mark P. Carthy | M | 63 | 4 anni | |
| Richard Paul Kivel | M | 57 | 3 anni | |
| Harry Penner | M | 78 | 8 anni | |
| Si Moon Hwang | M | 55 | 3 anni | |
| Jordan P. Karp | M | 57 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 anni |
| Mads Krogsgaard Thomsen | M | 63 | 30 anni | |
| Donald W. Fallon | M | 69 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 anni |
| Rakesh Soni | M | 68 | 7 anni | |
| David Martin McIntosh | M | 65 | 11 anni | |
| Carsten Hellmann | M | 60 | - | |
| Richard Rodgers | M | 57 | 6 anni | |
| Michael E. Lewis | M | 72 | 9 anni | |
| Joseph J. Krivulka | M | 73 | 9 anni | |
| Hanne Damgaard Jensen | F | - | 4 anni | |
| Ely Benaim | M | 63 | 4 anni | |
| David Sack | M | - |
National Institute of Mental Health
| 4 anni |
| Grethe Nørskov Rasmussen | M | 62 | 11 anni | |
| Jette Traulsen | M | - | 5 anni | |
| Søren Thuesen Pedersen | M | 59 | 24 anni | |
| Stig Strøbæk | M | 60 | 30 anni | |
| James D. Crapo | M | 81 | - | |
| Erik Michael Degn | M | - | 16 anni | |
| Henrik Poulsen | M | 57 | 1 anni | |
| Stephanie McSwain | F | - | - | |
| Lars Green | M | 57 | 27 anni | |
| Peter Jens Lindholm Kurtzhals | M | - | 28 anni | |
| Henrik Juuel | M | 59 | - | |
| Leif Kongerslev | M | 71 | - | |
| René Djurup | M | - | 4 anni | |
| Christopher Stanley | M | - | - | |
| Liselotte Hyveled | F | 58 | 26 anni | |
| Zaiton binti Jamaluddin | F | 65 | 8 anni | |
| Zhong Zhao | M | 57 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 6 anni |
| Tae-Heum Jeong | M | - | 14 anni | |
| Michael Kelly | M | 59 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 3 anni |
| Jack Nielsen | M | 60 | 11 anni | |
| Peder Holk Nielsen | M | 67 | 5 anni | |
| Jan Öhrström | M | 67 | 9 anni | |
| Steven Paul | M | 73 |
National Institute of Mental Health
| 5 anni |
| Carsten Boess | M | 57 | 13 anni | |
| Shayne C. Gad | M | - | - | |
| Anker Gunvald Lundemose | M | 63 | 4 anni | |
| Nicholas Landekic | M | 65 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 5 anni |
| Valerie D. Riddle | M | 63 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Joseph Klein | M | 62 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 7 anni |
| Richard P. Burgoon | M | - | - | |
| Bruce Carter | M | 80 | 4 anni | |
| David P. Nowotnik | M | 75 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 4 anni |
| David P. Wright | M | 75 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 anni |
| Thomas Videbaek | M | 63 | - | |
| Claus Tycho Bræstrup | M | 79 | 10 anni | |
| Christian Hansen | M | 58 | 7 anni | |
| Thomas Dyrberg | M | 69 | 10 anni | |
| Jan Mikkelsen | M | 65 | 11 anni | |
| Kirsten Drejer | M | 68 | 9 anni | |
| Francesca M. Cook | F | 58 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 anni |
| David Savello | M | 78 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 anni |
| Jens Jesper Ovesen | M | 67 | 4 anni | |
| Anders Hedegaard | M | 63 | 9 anni | |
| Lisa M. Nolan | M | 61 | 3 anni | |
| Susanne Hayes | F | - | 10 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 48 | 57.14% |
| Danimarca | 36 | 42.86% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Peter David Suzdak
- Contatti personali
